Cooley Advises Underwriters on Amedica IPO

New York – March 4, 2014 – Cooley LLP announced today that it advised the underwriters on Amedica Corporation's initial public offering. Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica now trades on the NASDAQ Capital Market under the symbol "AMDA."  

JMP Securities LLC acted as the sole book-running manager for the offering. Needham & Company LLC acted as co-manager for the offering.

The Cooley corporate and securities team advising the underwriters included partners Bo Yaghmaie, Charlie Kim and Darren DeStefano, as well as associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones, Mark Ballantyne and Dani Nazemian. Critical support for the offering was provided by partners Natasha Leskovsek and Drew Gantt and associates Phil Mitchell and David Sclar (health care & life sciences regulatory); partner Scott Talbot and associate Scott Weston (intellectual property); special counsel Michelle Lara (compensation & benefits) and partner Susan Philpot (tax). 
 
In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.